Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Bausch Health Companies Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Bausch Health Companies yıllık ortalama 29.8% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar declining at 0.3% annual. Gelirler yılda ortalama 0.9% oranında büyüyor .

Anahtar bilgiler

29.8%

Kazanç büyüme oranı

30.5%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	6.0%
Gelir büyüme oranı	0.9%
Özkaynak getirisi	n/a
Net Marj	-5.1%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely

Sep 19

Investors Don't See Light At End Of Bausch Health Companies Inc.'s (NYSE:BHC) Tunnel And Push Stock Down 28%

Aug 06

2 Red Alerts On Bausch Health Companies

Jul 25

The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%

May 21

Bausch Health Companies (NYSE:BHC) Strong Profits May Be Masking Some Underlying Issues

Nov 10

Bausch Health Companies Q3 2022 Earnings Preview

Nov 02

Bausch Health: Long-Term Need To Place Stops For Protection

Sep 28

Bausch Health Companies: Equity Stub Would Benefit From Ambitious Spinoff

Sep 21

Gelir ve Gider Dağılımı

Bausch Health Companies nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NYSE:BHC Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	9,202	-471	3,090	612
31 Mar 24	8,966	-455	2,965	612
31 Dec 23	8,757	-592	2,895	604
30 Sep 23	8,542	-963	2,789	594
30 Jun 23	8,350	-186	2,720	574
31 Mar 23	8,150	-357	2,652	545
31 Dec 22	8,124	-225	2,531	529
30 Sep 22	8,127	254	2,514	504
30 Jun 22	8,192	43	2,490	492
31 Mar 22	8,325	-407	2,504	480
31 Dec 21	8,434	-948	2,492	465
30 Sep 21	8,451	-1,170	2,472	467
30 Jun 21	8,478	-1,287	2,423	449
31 Mar 21	8,042	-1,018	2,299	442
31 Dec 20	8,027	-560	2,367	452
30 Sep 20	8,038	-1,923	2,395	447
30 Jun 20	8,109	-2,043	2,475	467
31 Mar 20	8,597	-1,888	2,600	476
31 Dec 19	8,601	-1,788	2,554	471
30 Sep 19	8,498	-616	2,512	477
30 Jun 19	8,425	-917	2,478	461
31 Mar 19	8,401	-1,619	2,469	438
31 Dec 18	8,380	-4,148	2,473	413
30 Sep 18	8,422	-3,291	2,486	383
30 Jun 18	8,505	-1,640	2,495	357
31 Mar 18	8,610	-805	2,512	357
31 Dec 17	8,724	2,404	2,582	361
30 Sep 17	8,964	1,376	2,609	364
30 Jun 17	9,224	-1,143	2,645	384
31 Mar 17	9,411	-1,407	2,657	414
31 Dec 16	9,674	-2,409	2,782	421
30 Sep 16	10,024	-2,280	2,826	424
30 Jun 16	10,332	-1,013	2,865	424
31 Mar 16	10,644	-764	2,879	381
31 Dec 15	10,442	-292	2,700	334
30 Sep 15	9,906	596	2,481	298
30 Jun 15	9,175	822	2,288	255
31 Mar 15	8,484	1,001	2,118	241
31 Dec 14	8,200	881	2,026	246
30 Sep 14	8,043	502	1,952	246
30 Jun 14	7,529	-746	1,804	236
31 Mar 14	6,583	-861	1,545	194
31 Dec 13	5,766	-866	1,305	157

Kaliteli Kazançlar: BHC şu anda kârlı değil.

Büyüyen Kar Marjı: BHC şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: BHC kârlı değildir, ancak son 5 yılda zararlarını yılda 29.8% oranında azaltmıştır.

Büyüme Hızlandırma: BHC 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: BHC kârlı olmadığından, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( 13% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: BHC 'un yükümlülükleri varlıklarından fazla olduğundan Özsermaye Getirisi'ni hesaplamak zordur.

Bausch Health Companies Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bausch Health Companies Inc. to Report Q2, 2024 Results on Aug 01, 2024

First quarter 2024 earnings: EPS misses analyst expectations

Bausch Health Companies Inc. to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Bausch Health Companies Inc. to Report Q4, 2023 Results on Feb 22, 2024

Recent updates

Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely

Price target decreased by 18% to US$7.79

Health Canada Approves the Bausch Health's (Pr)CABTREO Topical Gel

Executive VP & General Counsel exercised options and sold US$318k worth of stock

Investors Don't See Light At End Of Bausch Health Companies Inc.'s (NYSE:BHC) Tunnel And Push Stock Down 28%

Price target decreased by 11% to US$8.36

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bausch Health Companies Inc. Raises Earnings Guidance for the Full Year 2024

2 Red Alerts On Bausch Health Companies

Bausch Health Companies Inc. Announces Appointment of Aimee Lenar as Executive Vice President, US Pharma

Bausch Health Companies Inc. to Report Q2, 2024 Results on Aug 01, 2024

Price target decreased by 7.7% to US$9.56

The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%

Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

Bausch Health Companies Inc. Approves Directorate Appointments

Why Bausch Health Stock Plunged After Posting First-Quarter 2024 Results

First quarter 2024 earnings: EPS misses analyst expectations

Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health Companies Inc. to Report Q1, 2024 Results on May 02, 2024

Price target increased by 10% to US$10.33

Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults

Insufficient new directors

Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma

Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall from profit to US$0.03 loss

Bausch Health Companies Inc., Annual General Meeting, May 14, 2024

Bausch Health Companies Inc. to Report Q4, 2023 Results on Feb 22, 2024

Bausch Health Companies Inc. Announces the U.S. Launch of CABTREO Topical Gel

Bausch Health Companies Inc. and Salix Pharmaceuticals Ltd. Provides Update on Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute

Bausch Health Companies Inc. Announces Positive Topline Results from Global Phase 2 Study Evaluating Amiselimod (An S1p Antagonist) to Treat Ulcerative Colitis

Bausch Health, Canada Announces DUOBRII Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec's Public Drug Plan

Bausch Health: $20bn Debt Is A Mighty Elephant In The Room

Consensus EPS estimates fall by 89%, revenue upgraded

New major risk - Negative shareholders equity

No longer forecast to breakeven

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?

FDA Approves Bausch Health Companies Inc. and Its Dermatology Business, Ortho Dermatologics's Cabtreo Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older

Consensus EPS estimates fall by 31%

Bausch Health Companies Inc. to Report Q3, 2023 Results on Nov 02, 2023

Consensus EPS estimates fall from profit to US$0.49 loss

Bausch Health's Debt Dilemma: Strategic Decisions And Financial Metrics

Price target increased by 11% to US$9.50

Bausch Health Companies Inc. Announces Executive Changes

Bausch Health Companies Inc. Announces New Treatment PrUCERIS (Budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults

Executive VP & CFO exercised options to buy US$1.1m worth of stock.

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Consensus EPS estimates increase from loss to US$0.11 profit

Bausch Health Companies Inc. Raises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.072 (vs US$0.40 loss in 2Q 2022)

Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of Bausch Health Companies Inc

Is Bausch Health Companies (NYSE:BHC) A Risky Investment?

Bausch Health Companies Inc. to Report Q2, 2023 Results on Aug 03, 2023

Bausch + Lomb: $2.5bn M&A Deal Shows It Hasn't Learned From Parent's Mistakes

New major risk - Financial position

Consensus EPS estimates fall by 299%

Price target decreased by 29% to US$8.50

What To Do After Bausch Health Stock Plunged By Nearly 9% Again

Consensus EPS estimates upgraded to US$0.18 loss

Price target decreased by 8.9% to US$11.92

Consensus EPS estimates upgraded to US$0.33 loss

Forecast to breakeven in 2025

First quarter 2023 earnings: EPS misses analyst expectations

Bausch Health Companies Inc. Provides Consolidated Earnings Guidance for the Full Year 2023

Bausch Health Companies (NYSE:BHC) Has No Shortage Of Debt

Forecast breakeven date pushed back to 2025

CEO & Director exercised options to buy US$115k worth of stock.